Optimizing the use of biological therapy in patients with inflammatory bowel disease
about
Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel diseaseCurrent stage in inflammatory bowel disease: What is next?Epitopes in α8β1 and other RGD-binding integrins delineate classes of integrin-blocking antibodies and major binding loops in α subunitsReinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.The anti-inflammatory effect and potential mechanism of cardamonin in DSS-induced colitisOptimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Insights on the use of biosimilars in the treatment of inflammatory bowel disease.Top-down approach to biological therapy of Crohn's disease.Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.The Role of Temporary Fecal Diversion.Ascorbic acid ameliorates oxidative stress and inflammation in dextran sulfate sodium-induced ulcerative colitis in mice.Reversal of Immunogenicity in Inflammatory Bowel Disease.A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease.Evidence-based management of gastrointestinal diseases.Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin AmericaFood and Drug Administration guidances on biosimilars: an update for the gastroenterologistBiologic treatment of Japanese patients with inflammatory bowel disease
P2860
Q26768500-AD0E73FD-B686-45FC-B2A3-706A7929D6C3Q26777429-AC4CEA1A-8221-4484-8242-574FC1761271Q28607846-1995472C-C25A-43C7-A864-F7D87E74A60AQ31113830-41AB2CDA-14C0-414A-A80D-64FE973E06A2Q36122823-706DE5A2-8F8B-41E2-A5CF-5091F3F0E207Q38549995-06BDF7F7-4F77-4A54-A99A-37B6241244E6Q38735477-F481DA25-FF35-429E-8187-25C793AF694FQ38764671-5F1883CA-36ED-4D40-AA48-51D1DD2E3952Q38869663-5E83ECEC-2F4B-40BD-899F-CAA72F8189D0Q39371316-30DD1DC3-058F-4F88-8F62-1AA4D8CD0844Q39419599-5007426C-E62E-49A7-B24C-539F363484B4Q41845144-B94D868B-BDBE-4824-8B4B-820AF302CD61Q41882145-40BB3141-2EB7-45F3-A6A5-84646BB7C703Q42369594-2B49AC0F-536E-4113-91AA-256E0D8383E4Q43143178-BA05738C-2F52-43A9-A466-42C1D2A76096Q55441867-249977F8-CD12-41A0-8CDC-5DF2CA9DB3F2Q57173064-EB010D9A-E934-4883-9AFB-1ED9917EF131Q57298239-ED4103F0-D09F-453E-9517-EB3E34F332E3Q58544626-57AEC700-568C-4D3B-AF44-D5DFB9012486
P2860
Optimizing the use of biological therapy in patients with inflammatory bowel disease
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@ast
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@en
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@nl
type
label
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@ast
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@en
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@nl
prefLabel
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@ast
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@en
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@nl
P2860
P921
P356
P1476
Optimizing the use of biological therapy in patients with inflammatory bowel disease
@en
P2093
A. C. Moss
P2860
P356
10.1093/GASTRO/GOU087
P407
P577
2015-02-01T00:00:00Z